Across the recent three months, 18 analysts have shared their insights on Biogen (NASDAQ:BIIB), expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

Jan 27 (Reuters) - Sage Therapeutics (SAGE.O), opens new tab said on Monday that its board has unanimously rejected Biogen’s (BIIB.O), opens new tab $469 million offer, stating it "significantly ...

Biogen on Wednesday forecast 2025 profit below last year's levels and Wall Street expectations on Wednesday, hit by a strong dollar and a sharp drop in sales as its multiple sclerosis drugs ...

Biogen BIIB and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the approval of Leqembi (lecanemab) for mild cognitive impairment due to ...